A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
about
KRAS mutational analysis for colorectal cancer. Application: pharmacogenomicEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabEGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysisIdentification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinomaAllele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian PopulationKRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practiceGenetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancerGenetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisSimul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling.Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer OutcomeMolecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma.Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.EGFR-targeted therapies in lung cancer: predictors of response and toxicityValidation of analytic methods for biomarkers used in drug developmentPharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.Evolving role of cetuximab in the treatment of colorectal cancer.FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer.Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.Identification of novel markers for 5-FU and FOLFOX toxicity.Association between EGFR gene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients.
P2860
Q21128654-40B48D6D-82C4-4092-A3C4-7C9E58A16C84Q24652337-5FCB8972-34A1-4A97-B004-E2CA74E514F9Q26865056-0EA80823-C7BF-4EAB-93D5-D9A3857D4CA3Q28385950-D193BAE4-2362-4BA2-BBF3-E71F23C7851BQ28397131-505658C9-3EEE-42C3-916F-0642F50408C2Q33759960-8BBF34CE-245D-4002-BC59-2DE515BB0189Q33779432-1E2A3779-F69D-4BC1-A537-A8EC53E7269CQ34239801-5BBF0523-8D74-45C5-AEE9-2485190F280BQ34381843-10A65175-044C-447A-9FA6-758434154C06Q35120828-E9E0BF26-3750-4309-97CD-E4F237092C86Q35627924-E3F74DBA-B4A4-4F90-A49C-F2BD9BC3C4EBQ36012730-674DA38E-9F75-497F-9978-659265018440Q36039967-3C6BBBD7-4ADC-40B1-AA91-1D76292A06CFQ36159205-68E20764-20BC-4BB4-A839-271E1CDAC806Q36656187-E95D9CF3-236F-4F78-83F0-495AA0683B61Q36724092-F2CC901C-772B-4E9F-9BE3-92C5018C9854Q36964450-E422EDDA-3B28-4164-A46C-DCC3545971B2Q37160173-5CFAE212-C885-4CC6-A391-FB384D6C7431Q37284255-9BB901CA-142B-47AC-B484-8CE5E45DC50EQ37312970-DB829145-91D7-4810-A30C-DF70A1794FA3Q37378581-6C6D621A-218F-48C9-AC09-3A92AE674203Q37707275-91FE32A0-ADDF-4607-9FCD-05485CA84D8FQ38042875-D488AB72-E5A4-4FBE-A238-34D711AFD4ECQ39421577-615D8902-C78E-4B9F-8071-58B1F6BE532FQ40014365-E086D8AF-D499-4641-B396-9AB3F63CB727Q42218820-2396F0A0-CD87-4389-9C2F-A59A57A2F7A5Q42545098-76CF47B0-55A1-4A8F-8D0B-A77203F35F0CQ44740671-BB307F5F-1B51-427F-862E-879D22EAD540Q46427740-6373BF8A-357D-4354-B0E0-FE0B40FF9EF0Q48364519-B49454A0-D2A5-49B6-9FC2-40C6375FA6AFQ49175955-9DA7532E-7712-4D09-BCC4-FAC7F419FAF1Q54336793-842D9E83-229B-4AB5-B7FB-CA6594748CA7
P2860
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@ast
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@en
type
label
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@ast
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@en
prefLabel
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@ast
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@en
P2093
P2860
P356
P1433
P1476
A polymorphism of EGFR extrace ...... ing cetuximab-based treatment.
@en
P2093
Anthony Gonçalves
Arnaud Lagarde
Benjamin Esterni
Bernard Lelong
Brynn Taylor-Smedra
Daniel Birnbaum
François Bertucci
Frédéric Viret
Geneviève Monges
Jean-Paul Borg
P2860
P2888
P356
10.1186/1471-2407-8-169
P407
P577
2008-06-10T00:00:00Z
P5875
P6179
1015432296